DIAGNOS Inc. (CVE:ADK – Get Free Report) shares traded down 3.6% on Tuesday . The company traded as low as C$0.25 and last traded at C$0.27. 158,300 shares were traded during mid-day trading, an increase of 71% from the average session volume of 92,336 shares. The stock had previously closed at C$0.28.
DIAGNOS Stock Down 3.6 %
The stock’s 50 day simple moving average is C$0.34 and its two-hundred day simple moving average is C$0.33. The firm has a market cap of C$21.58 million, a P/E ratio of -6.63 and a beta of -0.44. The company has a debt-to-equity ratio of 245.28, a current ratio of 0.39 and a quick ratio of 0.68.
DIAGNOS (CVE:ADK – Get Free Report) last announced its quarterly earnings data on Wednesday, August 21st. The company reported C($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C($0.02) by C$0.01. The company had revenue of C$0.04 million for the quarter, compared to analysts’ expectations of C$0.07 million. As a group, research analysts forecast that DIAGNOS Inc. will post -0.02 earnings per share for the current year.
DIAGNOS Company Profile
DIAGNOS Inc provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes.
Read More
- Five stocks we like better than DIAGNOS
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- How to Read Stock Charts for Beginners
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- How to Capture the Benefits of Dividend Increases
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for DIAGNOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DIAGNOS and related companies with MarketBeat.com's FREE daily email newsletter.